UroGen Pharma, Inc.

Clinical trials sponsored by UroGen Pharma, Inc., explained in plain language.

Now part of UroGen Pharma Ltd. URGN NASDAQ

A biopharmaceutical company developing urological cancer treatments.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Not yet recruiting 1

Can a Bladder-Instilled biologic keep recurrent bladder cancer at bay?

Disease control Not yet recruiting

This early-phase trial is testing a new biologic drug, UGN-501, for people whose non-muscle invasive bladder cancer has returned after previous treatment. The drug is given directly into the bladder through a catheter once a week for six weeks, with possible quarterly maintenance…

Phase 1 • Sponsor: UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. • Aim: Disease control

Last updated Jul 26, 2026 00:00 UTC

UroGen Pharma, Inc.

Can a Bladder-Instilled biologic keep recurrent bladder cancer at bay?